Sanofi, Radiomedix, and OranoMed Sign Revolutionary Licensing Agreement for Next-Gen Radioligand Medicine
Sanofi, RadioMedix, and Orano Med have partnered to advance AlphaMedixTM, a treatment for a rare cancer known as neuroendocrine...
New Clinical Trial Technology Innovations at Veeva R&D And Quality Summit
The 2024 Veeva R&D and Quality Summit brought together industry leaders and professionals to discuss the latest clinical trial...
Cancer Therapies Revolutionized: Tetraspecific Antibodies Promise Breakthroughs in 2029
The biomedical field is witnessing a groundbreaking era with the advent of tetraspecific antibodies. These antibodies, representing the next...
Genesis & Gilead: A Novel Discovery Together
Gilead Sciences and Genesis Therapeutics have formed a collaboration to develop novel therapies through generative AI technology. Genesis’ GEMS...
AiCure H.code Patient Engagement Platform Unveiled at dpharm 2024
AiCure, a pioneer in clinical trial monitoring and patient engagement, will debut its innovative H.Code platform at the DPHARM...
Aditxt and Evofem Secure Merger to Empower Women’s Health
Aditxt and Evofem Biosciences have agreed to merge, creating an alliance focused on accelerating health innovations in women’s healthcare....
Silexion Therapeutics Unveils Pioneering RNAi Technology from Silexion Therapeutics for Revolutionizing the Fight Against KRAS-Driven Cancers
Silexion’s proprietary LODER™ platform enables targeted oncogene silencing, using siRNA to block the production of oncogenic proteins. This approach...
Innate Pharma’s Monalizumab NeoCOAST-2 Phase 2 Trial Reports Encouraging Outcomes in Early-Stage Lung Cancer
The NeoCOAST-2 trial evaluated the efficacy and safety of treatments in patients with early-stage non-small cell lung cancersmall cell...
How to Employ the Best Strategies From Your Clinical Trial Technology
Welcome to the Veeva R&D and Quality Summit. Today, we have the pleasure of speaking with Rylan Collins, VP...
AstraZeneca TROP2 Biomarker Predicts Lung Cancer Treatment Outcomes
An exploratory analysis of the TROPION-Lung01 phase 3 trial revealed TROP2 expression, measured using AstraZeneca’s computational pathology platform, as...